Acriflavine in the Treatment of Gonorrhoea—An Experimental and Clinical Study

Davis, Edwin; Harrell, Brian

doi:10.1016/s0022-5347(17)74204-8

Cited by 6 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ACF has repeatedly shown to be an efficient HIF-1α inhibitor with anti-tumor effects along with its safe use in vivo, thus allowing its integration in clinical trials along with other conventional therapy for diseases other than cancer (Table 3). The first-ever published administration of ACF in patients, with promising results, was for the treatment of gonorrhea by daily irri-gations of the bladder [61]. ACF was also used later in 1930 to treat severe undulant fever and its complications.…”

Section: Human Uses Doses and Safetymentioning

confidence: 99%

Repurposing of Acriflavine to Target Chronic Myeloid Leukemia Treatment

Nehme

Hallal

Dor

et al. 2021

CMC

View full text Add to dashboard Cite

: Drug repurposing has lately received increasing interest in several diseases especially in cancers due to its advantages in facilitating the development of new therapeutic strategies, by adopting a cost-friendly approach and avoiding the strict Food and Drug Administration (FDA) regulations. Acriflavine (ACF) is an FDA approved molecule that has been extensively studied since 1912 with antiseptic, trypanocidal, anti-viral, anti-bacterial and anti-cancer effects. ACF has been shown to block the growth of solid and hematopoietic tumor cells. Indeed, ACF acts as an inhibitor of various proteins including DNA-dependent protein kinases C (DNA-PKcs), topoisomerase I and II, hypoxia-inducible factor 1α (HIF-1α), in addition to its recent discovery as an inhibitor of the signal transducer and activator of transcription (STAT). Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder characterized by the expression of the constitutively active tyrosine kinase BCR-ABL. This protein allows the activation of several signaling pathways known for their role in cell proliferation and survival such as JAK/STAT pathway. CML therapy, based on tyrosine kinase inhibitors (TKIs), such as imatinib (IM), is highly effective. However, 15% of patients are refractory to IM, where in some cases 20-30% of patients become resistant. Thus, we suggest the repurposing of ACF in CML after IM failure or in combination with IM to improve the antitumor effects of IM. In this review, we present the different pharmacological properties of ACF along with its anti-leukemic effects in the hope of its repurposing in CML therapy.

show abstract

Section: Human Uses Doses and Safetymentioning

confidence: 99%

Repurposing of Acriflavine to Target Chronic Myeloid Leukemia Treatment

Nehme

Hallal

Dor

et al. 2021

CMC

View full text Add to dashboard Cite

show abstract

“…It has similarly been found that Gram-positive bacteria are more susceptible to quinine and hydrocuprein derivatives (Traube (54), Bieling (55)), to iodine (Breinl (56)) and to mesohematin and to magnesium and manganese derivatives of mesoporphyrin (Kammerer (57)). E. G. Davis and his coworkers (58)(59)(60)(61)(62) have studied a number of dyes, mercury derivatives and compounds related to phenolsulphonphthalein with the intent to find a suitable urinary antiseptic. Davis (24) has recently published a summary of his findings for over 200 dyes.…”

Section: The Toxicity Op the Dyesmentioning

confidence: 99%